Corporate, Commercial & Regulatory

Impressive depth of specialised experience

Van Bael & Bellis advises multinational clients on corporate, commercial and regulatory issues in the EU and Belgium.

Discover our expertise
  • "The lawyers are excellent; very responsive and to the point."

    Chambers Europe

Latest news

Sign up for updates

Subscribe to our updates

Please select the practice areas you are interested in: *

Get in touch

Please fill out the form below along with your query and someone from the team will get back to you. Alternatively you can email [email protected]

Recommendations

  • The quality of the advice is great - we have been asking some complex questions and they have given clear and to-the-point advice and have been very proactive in providing alternative solutions.

    Chambers Europe
  • Van Bael & Bellis has ‘impressive knowledge of dispute resolution, including mediation’. The firm is notable for its strong regulatory and administrative law contentious practice as well as its impressive life sciences sector presence.

    Legal 500
  • They patiently try to understand the mentality of people in different cultures and pay full respect to that. This attitude is rare in a highly expert world. We are fully satisfied with their practice and the results therefrom.

    IFLR1000
  • They are very responsive, and experienced in pharma and compliance-related matters. They always indicate the timelines of the work they do and keep the client informed on the status of the work.

    Chambers Europe

Team focus

Van Bael & Bellis is well known for its client-centred approach, commitment to excellence, exceptional client service and personalised attention.

Get in touch with our Corporate, Commercial & Regulatory teams today

Recent publications

Sign up for updates
    • 01/12/2020
    • Articles

    Commission Tables Data Governance Act

    On 25 November 2020, the European Commission proposed a Regulation on data governance (Data Governance Act) to better exploit the potential of ever-growing data in a trustworthy European framework. The proposal is the first of a set of measures announced in the 2020 European strategy for data (available here). According to the Commission, the proposed Regulation offers a new form of data governance and establishes an alternative model to the data-handling practices of the big technology platforms. The model is based on the neutrality and transparency of data intermediaries as organisers of data sharing or pooling. Please click the link below for a short article on this proposal.

    Read more
    • 27/11/2020
    • Articles

    European Commission Fines Cephalon and Teva On Account of "Pay-for-Delay" Patent Settlement Agreement

    On 26 November 2020, the European Commission (the Commission) brought to an end a long running competition case by finding against Cephalon and Teva on account of a “pay-for-delay” patent settlement agreement involving modafinil, the active substance of a sleeping disorder medicine (see, attached Commission press release).

    Read more
    • 26/11/2020
    • Articles

    European Commission Presents Pharmaceutical Strategy for Europe

    On 25 November 2020, the European Commission (the Commission) unveiled its Pharmaceutical Strategy for Europe (PSE), a wide-ranging document that discusses a series of broad policy statements, tentative considerations and concrete measures to tackle the many challenges faced by the pharmaceutical sector and its diverse stakeholders (see, attached Commission Communication (2020) 761 final; Commission press release; and Commission Q&A). The announcement follows an extensive period of consultation, study and preparation (see, Van Bael & Bellis Life Sciences News Alerts of 20 October 2020; 12 August 2020; 17 June 2020; 3 June 2020; and 28 May 2020).

    Read more
Keep updated Sign up for VBB insights

Be the first amongst your peers to get the latest publications and insights in Corporate, Commercial & Regulatory law.